CA
XENE icon

CoreCap Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

CoreCap Advisors’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.81K Buy
30
+13
+76% +$722 ﹤0.01% 2561
2026
Q1 		$989 Hold
17
– – ﹤0.01% 2535
2025
Q4 		$762 Buy
+17
New +$714 ﹤0.01% 2643

Other funds holding XENE

PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
EWM
Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
HIA
Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

CoreCap Advisors's XENE Position: Q2 2026 in Review

CoreCap Advisors increased its Xenon Pharmaceuticals (XENE) stake by 76% in Q2 2026, buying an estimated $722 and bringing the position to 30 shares worth $1.81K. The position accounts for ﹤0.01% of the portfolio, ranked #2561.

CoreCap Advisors first reported a position in XENE in Q4 2025 and has held it in 3 quarters since. 14 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • CoreCap Advisors held 30 shares of Xenon Pharmaceuticals worth $1.81K as of Q2 2026.
  • CoreCap Advisors bought 13 Xenon Pharmaceuticals shares in Q2 2026, an estimated $722.
  • Xenon Pharmaceuticals made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #2561 holding.
  • CoreCap Advisors first reported a position in Xenon Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 14 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.